Zacks Investment Research Downgrades Scpharmaceuticals (NASDAQ:SCPH) to Hold

Zacks Investment Research lowered shares of Scpharmaceuticals (NASDAQ:SCPH) from a buy rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports.

According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “

Separately, ValuEngine downgraded Scpharmaceuticals from a buy rating to a hold rating in a report on Tuesday, August 6th.

Scpharmaceuticals stock traded up $0.35 during mid-day trading on Wednesday, hitting $5.92. The company had a trading volume of 5,878 shares, compared to its average volume of 59,923. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.10. Scpharmaceuticals has a 12 month low of $2.44 and a 12 month high of $7.85. The stock’s 50 day moving average price is $6.27 and its two-hundred day moving average price is $4.46.

Scpharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.10. As a group, equities analysts predict that Scpharmaceuticals will post -1.86 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Morgan Stanley lifted its holdings in shares of Scpharmaceuticals by 32.0% during the second quarter. Morgan Stanley now owns 13,633 shares of the company’s stock valued at $43,000 after purchasing an additional 3,306 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Scpharmaceuticals by 55.8% during the second quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock valued at $118,000 after purchasing an additional 13,225 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Scpharmaceuticals during the first quarter valued at $51,000. Paloma Partners Management Co bought a new position in shares of Scpharmaceuticals during the second quarter valued at $96,000. Finally, Alambic Investment Management L.P. bought a new position in shares of Scpharmaceuticals during the second quarter valued at $191,000. 39.67% of the stock is currently owned by hedge funds and other institutional investors.

Scpharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

Further Reading: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.